The bispecific antibodies, T-cell activators, attempt to bring the two cell types closer together, thereby stimulating the T-cell to attack the cancer cell. At least 12 such T-cell activators have been approved for the treatment of cancer, including leukemia & myeloma. @heidiledford.bsky.social
Cancer-fighting antibodies with a one-two punch take aim at tumoursBispecific antibodies, which bind to two targets, are sweeping into the clinic and are prompting even more elaborate versions.go.nature.com